JP6148618B2 - 呼吸器の病態又は疾患の治療のための化合物 - Google Patents

呼吸器の病態又は疾患の治療のための化合物 Download PDF

Info

Publication number
JP6148618B2
JP6148618B2 JP2013504064A JP2013504064A JP6148618B2 JP 6148618 B2 JP6148618 B2 JP 6148618B2 JP 2013504064 A JP2013504064 A JP 2013504064A JP 2013504064 A JP2013504064 A JP 2013504064A JP 6148618 B2 JP6148618 B2 JP 6148618B2
Authority
JP
Japan
Prior art keywords
ethoxy
asthma
pyridazin
benzo
hrv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013504064A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013523844A (ja
JP2013523844A5 (enExample
Inventor
ニコラス ランバート、ジョン
ニコラス ランバート、ジョン
ライアン、ジェイン
マリー ウィルソン、ジャネット
マリー ウィルソン、ジャネット
Original Assignee
バイオウタ サイエンティフィック マネジメント プロプライエタリー リミテッド
バイオウタ サイエンティフィック マネジメント プロプライエタリー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2010901601A external-priority patent/AU2010901601A0/en
Application filed by バイオウタ サイエンティフィック マネジメント プロプライエタリー リミテッド, バイオウタ サイエンティフィック マネジメント プロプライエタリー リミテッド filed Critical バイオウタ サイエンティフィック マネジメント プロプライエタリー リミテッド
Publication of JP2013523844A publication Critical patent/JP2013523844A/ja
Publication of JP2013523844A5 publication Critical patent/JP2013523844A5/ja
Application granted granted Critical
Publication of JP6148618B2 publication Critical patent/JP6148618B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2013504064A 2010-04-15 2011-04-14 呼吸器の病態又は疾患の治療のための化合物 Active JP6148618B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2010901601 2010-04-15
AU2010901601A AU2010901601A0 (en) 2010-04-15 Compound for the treatment of respiratory condition or disease
PCT/AU2011/000434 WO2011127538A1 (en) 2010-04-15 2011-04-14 Compound for treatment of respiratory condition or disease

Publications (3)

Publication Number Publication Date
JP2013523844A JP2013523844A (ja) 2013-06-17
JP2013523844A5 JP2013523844A5 (enExample) 2014-05-29
JP6148618B2 true JP6148618B2 (ja) 2017-06-14

Family

ID=44788654

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013504064A Active JP6148618B2 (ja) 2010-04-15 2011-04-14 呼吸器の病態又は疾患の治療のための化合物

Country Status (16)

Country Link
US (1) US20110257192A1 (enExample)
EP (1) EP2558097B1 (enExample)
JP (1) JP6148618B2 (enExample)
KR (1) KR20130106267A (enExample)
CN (2) CN105560245A (enExample)
AU (1) AU2011241478B2 (enExample)
BR (1) BR112012026244A2 (enExample)
CA (1) CA2796207A1 (enExample)
EA (1) EA025224B1 (enExample)
ES (1) ES2647223T3 (enExample)
IL (1) IL222244A0 (enExample)
MX (1) MX2012011938A (enExample)
NZ (1) NZ603040A (enExample)
SG (2) SG184430A1 (enExample)
WO (1) WO2011127538A1 (enExample)
ZA (1) ZA201207696B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL266301B2 (en) 2013-04-12 2023-03-01 Obschestvo S Ogranichennoi Otvetstvennostiyu Pharmenterprises History of glutarimide, their use, pharmaceutical preparation based on them and methods for producing history of glutarimide
KR20170012332A (ko) * 2014-06-20 2017-02-02 아비라겐 테라퓨틱스, 인코포레이티드 [2-[1-(6-메틸-3-피리다지닐)-4-피페리디닐]에톡시]-3-에톡시-1,2-벤즈이속사졸의 무수 결정성 유리 염기 형태
US20240350487A1 (en) * 2023-03-13 2024-10-24 Altesa BioSciences, Inc. Method of dosing vapendavir to treat enterovirus infections

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR213700A0 (en) * 2000-12-18 2001-01-25 Biota Scientific Management Pty Ltd Antiviral agents
WO2003068222A1 (en) * 2002-02-14 2003-08-21 Viropharma Incorporated Methods of reducing rhinovirus contagion and related compositions
WO2004073710A1 (en) * 2003-02-21 2004-09-02 Apodemus Ab Treatment of diseases caused by ljungan virus by using pleconaril
US9308199B2 (en) * 2004-04-29 2016-04-12 Honeywell International Inc. Medicament formulations
US20060069124A1 (en) * 2004-09-07 2006-03-30 Rao P S Use of MDL-100,907 for treatment of allergic and eosinophil mediated diseases
AR057623A1 (es) * 2005-11-28 2007-12-05 Omega Bio Pharma H K Ltd Materiales y metodos para el tratamiento de las infecciones virales
NZ590286A (en) 2008-05-27 2011-08-26 Biota Scient Management Phosphate and sulphate salts of 6-{ 2-[1-(6-methyl-3-pyrazinyl)-4-piperidinyl]ethoxy} -3-ethoxy-1,2-benzisoxazole
TW201016215A (en) 2008-07-17 2010-05-01 Schering Corp Compositions and uses of antiviral active pharmaceutical agents

Also Published As

Publication number Publication date
IL222244A0 (en) 2012-12-31
NZ603040A (en) 2015-03-27
EP2558097A1 (en) 2013-02-20
US20110257192A1 (en) 2011-10-20
EP2558097A4 (en) 2013-09-11
ES2647223T3 (es) 2017-12-20
KR20130106267A (ko) 2013-09-27
CN105560245A (zh) 2016-05-11
JP2013523844A (ja) 2013-06-17
BR112012026244A2 (pt) 2016-07-12
ZA201207696B (en) 2014-03-26
MX2012011938A (es) 2013-01-28
SG10201502391WA (en) 2015-05-28
WO2011127538A1 (en) 2011-10-20
CN102844032A (zh) 2012-12-26
AU2011241478A1 (en) 2012-11-01
EP2558097B1 (en) 2017-10-25
EA201201416A1 (ru) 2013-03-29
EA025224B1 (ru) 2016-12-30
AU2011241478B2 (en) 2016-12-01
SG184430A1 (en) 2012-11-29
CA2796207A1 (en) 2011-10-20

Similar Documents

Publication Publication Date Title
JP7169693B2 (ja) 呼吸器疾患の治療
US20250195544A1 (en) Fluticasone furoate in the treatment of copd
US12011453B2 (en) Medicament for prevention or treatment of rhinovirus infection
US20230218596A1 (en) Methods involving neutrophil elastase inhibitor alvelestat for treating coronavirus infection
CN117695284A (zh) 冠状病毒感染的治疗
JP6148618B2 (ja) 呼吸器の病態又は疾患の治療のための化合物
CN116744934A (zh) 用于治疗病毒性呼吸疾病的吸入性他汀类药物
GB2594480A (en) New treatment
WO2025235945A1 (en) Methods of treating viral infections using a fusion inhibitor
HK40058742B (zh) 呼吸性疾病的治疗
CN116782905A (zh) 治疗COVID-19和预防SARS-CoV-2感染的配制品和方法
US20220304959A1 (en) Treatment of long haulers syndrome with niclosamide

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140411

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140411

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150320

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150616

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150717

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150820

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20151209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160520

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170519

R150 Certificate of patent or registration of utility model

Ref document number: 6148618

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250